Commentary
Commentary
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
California
California’s weak job market is a cry for help. Is anyone listening?
California’s job market continues to suffer from largely self-inflicted wounds, despite the fact that the overall economy is growing. In April, Gov. Gavin Newsom projected that California’s economy had grown larger than Japan’s, making it the fourth largest in the world (if it were its own economy, which it’s not). ...
Blended Learning
The Double-Edged Sword Of AI In The Classroom
With the new school year started, one of the growing challenges facing students, parents, and teachers is how to address the classroom uses of AI, which has become a double-edged sword in the education process. Read the op-ed here.
Commentary
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Commentary
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank. According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase ...
Commentary
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...
Commentary
What socialized medicine really looks like
Most younger voters are rooting for a socialist president in the 2028 election, according to a new poll. In addition, more than three-quarters of voters younger than 40 believe that major industries such as health care, energy and Big Tech should be nationalized “to give more control and equity to ...
Commentary
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.
Commentary
Kennedy’s Vaccine Policies Put Americans at Risk in More Ways Than One
The effects of Kennedy’s vaccines policies are going to hurt Americans – and not just because more people are falling ill. Health experts, former CDC directors, and medical associations are gravely concerned that HHS Secretary RFK Jr.’s actions are risking Americans’ health and wellbeing. Nine former directors of the CDC ...
Commentary
Doctors and patients have endured enough pay cuts from Medicare
Doctors who treat Medicare beneficiaries are in for leaner times, judging from the program’s recently announced reimbursement update. And it will be those beneficiaries who will pay the price. The proposed changes to Medicare’s “fee schedule” would technically increase doctor reimbursement by 2.5%. But the government is also proposing to ...
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
California’s weak job market is a cry for help. Is anyone listening?
California’s job market continues to suffer from largely self-inflicted wounds, despite the fact that the overall economy is growing. In April, Gov. Gavin Newsom projected that California’s economy had grown larger than Japan’s, making it the fourth largest in the world (if it were its own economy, which it’s not). ...
The Double-Edged Sword Of AI In The Classroom
With the new school year started, one of the growing challenges facing students, parents, and teachers is how to address the classroom uses of AI, which has become a double-edged sword in the education process. Read the op-ed here.
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank. According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase ...
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...
What socialized medicine really looks like
Most younger voters are rooting for a socialist president in the 2028 election, according to a new poll. In addition, more than three-quarters of voters younger than 40 believe that major industries such as health care, energy and Big Tech should be nationalized “to give more control and equity to ...
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.
Kennedy’s Vaccine Policies Put Americans at Risk in More Ways Than One
The effects of Kennedy’s vaccines policies are going to hurt Americans – and not just because more people are falling ill. Health experts, former CDC directors, and medical associations are gravely concerned that HHS Secretary RFK Jr.’s actions are risking Americans’ health and wellbeing. Nine former directors of the CDC ...
Doctors and patients have endured enough pay cuts from Medicare
Doctors who treat Medicare beneficiaries are in for leaner times, judging from the program’s recently announced reimbursement update. And it will be those beneficiaries who will pay the price. The proposed changes to Medicare’s “fee schedule” would technically increase doctor reimbursement by 2.5%. But the government is also proposing to ...
